

---

## 6 References

1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. *CA Cancer J Clin* 2000, 50:7-33.
2. Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, Durant JR: A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). *J Clin Oncol* 1983, 1:126-134.
3. Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, Houghton AN: Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. *Cancer* 1993, 72:3091-3098.
4. Clark WH, Jr., From L, Bernardino EA, Mihm MC: The histogenesis and biologic behavior of primary human malignant melanomas of the skin. *Cancer Res* 1969, 29:705-727.
5. Ruiter DJ, Bhan AK, Harrist TJ, Sober AJ, Mihm MC, Jr.: Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevocellular proliferations and malignant melanoma. *J Immunol* 1982, 129:2808-2815.
6. Clark WH, Jr., Elder DE, Guerry Dt, Epstein MN, Greene MH, Van Horn M: A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. *Hum Pathol* 1984, 15:1147-1165.
7. Mihm MC, Jr., Fitzpatrick TB, Brown MM, Raker JW, Malt RA, Kaiser JS: Early detection of primary cutaneous malignant melanoma. A color atlas. *N Engl J Med* 1973, 289:989-996.
8. Tefany FJ, Barnetson RS, Halliday GM, McCarthy SW, McCarthy WH: Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. *J Invest Dermatol* 1991, 97:197-202.
9. Ferradini L, Mackensen A, Genevee C, Bosq J, Duvillard P, Avril MF, Hercend T: Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. *J Clin Invest* 1993, 91:1183-1190.
10. Mackensen A, Ferradini L, Carcelain G, Triebel F, Faure F, Viel S, Hercend T: Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. *Cancer Res* 1993, 53:3569-3573.
11. Mackensen A, Carcelain G, Viel S, Raynal MC, Michalaki H, Triebel F, Bosq J, Hercend T: Direct evidence to support the immunosurveillance concept in a human regressive melanoma. *J Clin Invest* 1994, 93:1397-1402.
12. Salvi S, Segalla F, Rao S, Arienti F, Sartori M, Bratina G, Caronni E, Anichini A, Clemente C, Parmiani G, et al.: Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. *Cancer Res* 1995, 55:3374-3379.
13. Mihm MC Jr.; [www.cancerresearch.org/immune99/martin\\_mihm.html](http://www.cancerresearch.org/immune99/martin_mihm.html).

14. Clark WH, Jr., Elder DE, Guerry Dt, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, Halpern AC: Model predicting survival in stage I melanoma based on tumor progression. *J Natl Cancer Inst* 1989, 81:1893-1904.
15. Clemente CG, Mihm MC, Jr., Bufalino R, Zurrada S, Collini P, Cascinelli N: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. *Cancer* 1996, 77:1303-1310.
16. Mihm MC, Jr., Clemente CG, Cascinelli N: Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. *Lab Invest* 1996, 74:43-47.
17. Schumacher K, Haensch W, Roefzaad C, Schlag PM: Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. *Cancer Res* 2001, 61:3932-3936.
18. Cho Y, Miyamoto M, Kato K, Fukunaga A, Shichinohe T, Kawarada Y, Hida Y, Oshikiri T, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Murakami S, Shinohara T, Itoh T, Okushiba S, Kondo S, Katoh H: CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. *Cancer Res* 2003, 63:1555-1559.
19. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. *N Engl J Med* 2003, 348:203-213.
20. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. *Cancer Res* 1998, 58:3491-3494.
21. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM: Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. *J Pathol* 1997, 182:318-324.
22. Hewitt HB, Blake ER, Walder AS: A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. *Br J Cancer* 1976, 33:241-259.
23. Boon T, Van Pel A: Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. *Proc Natl Acad Sci U S A* 1978, 75:1519-1523.
24. Van Pel A, Georlette M, Boon T: Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: immune rejection by syngeneic mice. *Proc Natl Acad Sci U S A* 1979, 76:5282-5285.
25. Van Pel A, Boon T: Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. *Proc Natl Acad Sci U S A* 1982, 79:4718-4722.
26. Renkvist N, Castelli C, Robbins PF, Parmiani G: A listing of human tumor antigens recognized by T cells. *Cancer Immunol Immunother* 2001, 50:3-15.

27. Van den Eynde BJ, Boon T: Tumor antigens recognized by T lymphocytes. *Int J Clin Lab Res* 1997, 27:81-86.
28. Sahin U, Tureci O, Pfreundschuh M: Serological identification of human tumor antigens. *Curr Opin Immunol* 1997, 9:709-716.
29. Rosenberg SA: A new era for cancer immunotherapy based on the genes that encode cancer antigens. *Immunity* 1999, 10:281-287.
30. Old LJ: Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. *Cancer Res* 1981, 41:361-375.
31. Dippold WG, Lloyd KO, Li LT, Ikeda H, Oettgen HF, Old LJ: Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. *Proc Natl Acad Sci U S A* 1980, 77:6114-6118.
32. Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ: GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. *J Exp Med* 1982, 155:1133-1147.
33. Nudelman E, Hakomori S, Kannagi R, Levery S, Yeh MY, Hellstrom KE, Hellstrom I: Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2. *J Biol Chem* 1982, 257:12752-12756.
34. Watanabe T, Pukel CS, Takeyama H, Lloyd KO, Shiku H, Li LT, Travassos LR, Oettgen HF, Old LJ: Human melanoma antigen AH is an autoantigenic ganglioside related to GD2. *J Exp Med* 1982, 156:1884-1889.
35. Irie RF, Giuliano AE, Morton DL: Oncofetal antigen: a tumor-associated fetal antigen immunogenic in man. *J Natl Cancer Inst* 1979, 63:367-373.
36. Tai T, Paulson JC, Cahan LD, Irie RF: Ganglioside GM2 as a human tumor antigen (OFA-I-1). *Proc Natl Acad Sci U S A* 1983, 80:5392-5396.
37. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. *J Exp Med* 1993, 178:489-495.
38. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, et al.: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. *J Exp Med* 1994, 180:35-42.
39. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL, Jr.: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. *Science* 1994, 264:716-719.
40. Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L: CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. *Nature* 1994, 369:67-71.

41. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schober I, Pfreundschuh M: Human neoplasms elicit multiple specific immune responses in the autologous host. *Proc Natl Acad Sci U S A* 1995, 92:11810-11813.
42. Wang RF, Wang X, Rosenberg SA: Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. *J Exp Med* 1999, 189:1659-1668.
43. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA: Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. *Science* 1999, 284:1351-1354.
44. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT: Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. *Immunol Rev* 2002, 188:22-32.
45. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. *Science* 1991, 254:1643-1647.
46. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. *J Exp Med* 1994, 179:921-930.
47. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. *J Exp Med* 1995, 182:689-698.
48. Boel P, Wildmann C, Sensi ML, Brasseur R, Renaud JC, Coulie P, Boon T, van der Bruggen P: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. *Immunity* 1995, 2:167-175.
49. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. *Proc Natl Acad Sci U S A* 1997, 94:1914-1918.
50. Meuwissen RL, Offenbergh HH, Dietrich AJ, Riesewijk A, van Iersel M, Heyting C: A coiled-coil related protein specific for synapsed regions of meiotic prophase chromosomes. *Embo J* 1992, 11:5091-5100.
51. Baba T, Niida Y, Michikawa Y, Kashiwabara S, Kodaira K, Takenaka M, Kohno N, Gerton GL, Arai Y: An acrosomal protein, sp32, in mammalian sperm is a binding protein specific for two proacrosins and an acrosin intermediate. *J Biol Chem* 1994, 269:10133-10140.
52. Vidaeus CM, von Kapp-Herr C, Golden WL, Eddy RL, Shows TB, Herr JC: Human fertilin beta: identification, characterization, and chromosomal mapping of an ADAM gene family member. *Mol Reprod Dev* 1997, 46:363-369.

53. Primakoff P, Myles DG: The ADAM gene family: surface proteins with adhesion and protease activity. *Trends Genet* 2000, 16:83-87.
54. Salehi AH, Xanthoudakis S, Barker PA: NRAGE, a p75 neurotrophin receptor-interacting protein, induces caspase activation and cell death through a JNK-dependent mitochondrial pathway. *J Biol Chem* 2002, 277:48043-48050.
55. Salehi AH, Roux PP, Kubu CJ, Zeindler C, Bhakar A, Tannis LL, Verdi JM, Barker PA: NRAGE, a novel MAGE protein, interacts with the p75 neurotrophin receptor and facilitates nerve growth factor-dependent apoptosis. *Neuron* 2000, 27:279-288.
56. Sasaki A, Masuda Y, Iwai K, Ikeda K, Watanabe K: A RING finger protein Praja1 regulates Dlx5-dependent transcription through its ubiquitin ligase activity for the Dlx/Msx-interacting MAGE/Necdin family protein, Dlxin-1. *J Biol Chem* 2002, 277:22541-22546.
57. Jordan BW, Dinev D, LeMellay V, Troppmair J, Gotz R, Wixler L, Sendtner M, Ludwig S, Rapp UR: Neurotrophin receptor-interacting mage homologue is an inducible inhibitor of apoptosis protein-interacting protein that augments cell death. *J Biol Chem* 2001, 276:39985-39989.
58. Jassim A, Ollier W, Payne A, Biro A, Oliver RT, Festenstein H: Analysis of HLA antigens on germ cells in human semen. *Eur J Immunol* 1989, 19:1215-1220.
59. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. *Proc Natl Acad Sci U S A* 1994, 91:3515-3519.
60. Robbins PF, el-Gamil M, Kawakami Y, Stevens E, Yannelli JR, Rosenberg SA: Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. *Cancer Res* 1994, 54:3124-3126.
61. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. *Proc Natl Acad Sci U S A* 1994, 91:6458-6462.
62. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. *J Exp Med* 1995, 181:799-804.
63. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA: Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. *J Exp Med* 1996, 184:2207-2216.
64. Derbinski J, Schulte A, Kyewski B, Klein L: Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. *Nat Immunol* 2001, 2:1032-1039.
65. Bowne WB, Srinivasan R, Wolchok JD, Hawkins WG, Blachere NE, Dyall R, Lewis JJ, Houghton AN: Coupling and uncoupling of tumor immunity and autoimmunity. *J Exp Med* 1999, 190:1717-1722.

66. Naftzger C, Takechi Y, Kohda H, Hara I, Vijayasaradhi S, Houghton AN: Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. *Proc Natl Acad Sci U S A* 1996, 93:14809-14814.
67. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, Boon T: A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. *Proc Natl Acad Sci U S A* 1995, 92:7976-7980.
68. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Buschenfelde KH, Beach D: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. *Science* 1995, 269:1281-1284.
69. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA: A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. *J Exp Med* 1996, 183:1185-1192.
70. Zorn E, Hercend T: A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. *Eur J Immunol* 1999, 29:592-601.
71. Robbins PF, el-Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA: Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. *J Immunol* 1995, 154:5944-5950.
72. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA: The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. *Nature* 1984, 312:513-516.
73. King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. *Science* 1985, 229:974-976.
74. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987, 235:177-182.
75. Yee C, Greenberg P: Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. *Nat Rev Cancer* 2002, 2:409-419.
76. Appay V, Rowland-Jones SL: The assessment of antigen-specific CD8+ T cells through the combination of MHC class I tetramer and intracellular staining. *J Immunol Methods* 2002, 268:9-19.
77. Valmori D, Pittet MJ, Vonarbourg C, Rimoldi D, Lienard D, Speiser D, Dunbar R, Cerundolo V, Cerottini JC, Romero P: Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A\*0201-associated tyrosinase peptide 368-376. *Cancer Res* 1999, 59:4050-4055.

78. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC, Cerundolo V: Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. *J Exp Med* 1998, 188:1641-1650.
79. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. *Nat Med* 1999, 5:677-685.
80. Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Lienard D, Lejeune F, Fleischhauer K, Cerundolo V, Cerottini JC, Romero P: High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. *J Exp Med* 1999, 190:705-715.
81. D'Souza S, Rimoldi D, Lienard D, Lejeune F, Cerottini JC, Romero P: Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. *Int J Cancer* 1998, 78:699-706.
82. Dunbar PR, Smith CL, Chao D, Salio M, Shepherd D, Mirza F, Lipp M, Lanzavecchia A, Sallusto F, Evans A, Russell-Jones R, Harris AL, Cerundolo V: A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. *J Immunol* 2000, 165:6644-6652.
83. Speiser DE, Lienard D, Pittet MJ, Batard P, Rimoldi D, Guillaume P, Cerottini JC, Romero P: In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. *Eur J Immunol* 2002, 32:731-741.
84. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. *J Exp Med* 1998, 187:1349-1354.
85. Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jager D, Arand M, Ritter G, Cerundolo V, Dupont B, Chen YT, Old LJ, Knuth A: Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. *Proc Natl Acad Sci U S A* 2000, 97:4760-4765.
86. Jager E, Jager D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S, Stockert E, Arand M, Old LJ, Knuth A: Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4\*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. *J Exp Med* 2000, 191:625-630.
87. Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki NK, Maki RG, Dupont B, Ritter G, Chen YT, Knuth A, Old LJ: Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. *Proc Natl Acad Sci U S A* 2003.

88. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K, Odermatt B, Hanahan D, Zinkernagel RM, Ohashi PS: Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. *J Exp Med* 1997, 186:645-653.
89. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, Hemmi S, Hengartner H, Zinkernagel RM: Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. *Nature* 2001, 411:1058-1064.
90. Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, Fu YX, Schreiber H: Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. *Immunity* 2002, 17:737-747.
91. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. *Cancer Res* 1999, 59:3128-3133.
92. Shimizu J, Yamazaki S, Sakaguchi S: Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. *J Immunol* 1999, 163:5211-5218.
93. Suttmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ: Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. *J Exp Med* 2001, 194:823-832.
94. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H: Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. *Proc Natl Acad Sci U S A* 1998, 95:1178-1183.
95. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, DelleMijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP: Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. *J Exp Med* 2003, 198:569-580.
96. Nasi ML, Meyers M, Livingston PO, Houghton AN, Chapman PB: Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside. *Melanoma Res* 1997, 7 Suppl 2:S155-162.
97. Minasian LM, Yao TJ, Steffens TA, Scheinberg DA, Williams L, Riedel E, Houghton AN, Chapman PB: A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. *Cancer* 1995, 75:2251-2257.
98. Steffens TA, Bajorin DF, Houghton AN: Immunotherapy with monoclonal antibodies in metastatic melanoma. *World J Surg* 1992, 16:261-269.
99. Keilholz U, Gore ME: Biochemotherapy for advanced melanoma. *Semin Oncol* 2002, 29:456-461.

100. Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD: Adoptive immunotherapy: Engineering T cell responses as biologic weapons for tumor mass destruction. *Cancer Cell* 2003, 3:431-437.
101. Dudley ME, Rosenberg SA: Adoptive-cell-transfer therapy for the treatment of patients with cancer. *Nat Rev Cancer* 2003, 3:666-675.
102. Wang E, Phan GQ, Marincola FM: T-cell-directed cancer vaccines: the melanoma model. *Expert Opin Biol Ther* 2001, 1:277-290.
103. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A: Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? *J Natl Cancer Inst* 2002, 94:805-818.
104. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. *Cancer Res* 2001, 61:6451-6458.
105. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. *J Exp Med* 1999, 190:1669-1678.
106. Schadendorf D, Paschen A, Sun Y: Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma. *Immunol Lett* 2000, 74:67-74.
107. Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK: Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. *Int J Cancer* 2000, 88:232-238.
108. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. *J Clin Invest* 2002, 109:409-417.
109. Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J: Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. *Cancer Res* 2003, 63:2127-2133.
110. Jaeger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J, Ilsemann C, Hagedorn M, Knuth A: Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. *Int J Cancer* 1996, 66:162-169.

111. Jager E, Gnjjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A: Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. *Proc Natl Acad Sci U S A* 2000, 97:12198-12203.
112. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. *Int J Cancer* 1999, 80:219-230.
113. Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM: Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. *J Immunol* 1999, 163:6292-6300.
114. Kammula US, White DE, Rosenberg SA: Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. *Cancer* 1998, 83:797-805.
115. Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG, Jr., Pinedo HM: Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. *Lancet* 1999, 353:345-350.
116. Forni G, Musso T, Santoni A, Giovarelli M: Local administration of interleukin-2 activates lymphocytes from tumor bearing mice to recruit host immunoreactivity and inhibit tumor growth. *Prog Clin Biol Res* 1987, 244:105-114.
117. Forni G, Fujiwara H, Martino F, Hamaoka T, Jemma C, Caretto P, Giovarelli M: Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy. *Cancer Metastasis Rev* 1988, 7:289-309.
118. Mach N, Dranoff G: Cytokine-secreting tumor cell vaccines. *Curr Opin Immunol* 2000, 12:571-575.
119. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. *Proc Natl Acad Sci U S A* 1993, 90:3539-3543.
120. Bausero MA, Panoskaltis-Mortari A, Blazar BR, Katsanis E: Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-gamma. *J Immunother Emphasis Tumor Immunol* 1996, 19:113-124.

121. Abe J, Wakimoto H, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H: Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: comparison of adenovirus- and retrovirus-mediated genetic transduction. *J Cancer Res Clin Oncol* 1995, 121:587-592.
122. Armstrong CA, Botella R, Galloway TH, Murray N, Kramp JM, Song IS, Ansel JC: Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. *Cancer Res* 1996, 56:2191-2198.
123. Krosi G, Korbek M, Krosi J, Dougherty GJ: Potentiation of photodynamic therapy-elicited antitumor response by localized treatment with granulocyte-macrophage colony-stimulating factor. *Cancer Res* 1996, 56:3281-3286.
124. Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW: Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. *J Immunol* 1996, 156:3858-3865.
125. Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K, Hamada H: Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. *Cancer Res* 1996, 56:1828-1833.
126. Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, Dranoff G, Pardoll DM, Mulligan RC, Simons JW: Demonstration of a rational strategy for human prostate cancer gene therapy. *J Urol* 1994, 151:622-628.
127. Shroyer DP, Bogaars H, Hearing VJ, Wanebo HJ: Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy. *J Exp Ther Oncol* 1996, 1:126-133.
128. Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G, Bigner DD: Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. *Proc Natl Acad Sci U S A* 1996, 93:10399-10404.
129. Dunussi-Joannopoulos K, Dranoff G, Weinstein HJ, Ferrara JL, Bierer BE, Croop JM: Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. *Blood* 1998, 91:222-230.
130. Kielian T, Nagai E, Ikubo A, Rasmussen CA, Suzuki T: Granulocyte/macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1alpha and accumulation of dendritic cells at vaccination sites in vivo. *Cancer Immunol Immunother* 1999, 48:123-131.

131. Yu JS, Burwick JA, Dranoff G, Breakefield XO: Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. *Hum Gene Ther* 1997, 8:1065-1072.
132. Qin H, Chatterjee SK: Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. *Hum Gene Ther* 1996, 7:1853-1860.
133. Lee CT, Wu S, Ciernik IF, Chen H, Nadaf-Rahrov S, Gabrilovich D, Carbone DP: Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. *Hum Gene Ther* 1997, 8:187-193.
134. Dong Z, Yoneda J, Kumar R, Fidler IJ: Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor. *J Exp Med* 1998, 188:755-763.
135. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H: The central role of CD4(+) T cells in the antitumor immune response. *J Exp Med* 1998, 188:2357-2368.
136. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. *Science* 1994, 264:961-965.
137. Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM: The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. *Cancer Res* 2001, 61:880-883.
138. Kaplan G, Walsh G, Guido LS, Meyn P, Burkhardt RA, Abalos RM, Barker J, Frindt PA, Fajardo TT, Celona R, et al.: Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. *J Exp Med* 1992, 175:1717-1728.
139. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. *Nature* 1998, 392:245-252.
140. Young JW, Inaba K: Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. *J Exp Med* 1996, 183:7-11.
141. Klein C, Bueler H, Mulligan RC: Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. *J Exp Med* 2000, 191:1699-1708.
142. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ: Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. *J Exp Med* 1996, 184:1953-1962.

143. Pulendran B, Lingappa J, Kennedy MK, Smith J, Teepe M, Rudensky A, Maliszewski CR, Maraskovsky E: Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. *J Immunol* 1997, 159:2222-2231.
144. Shurin MR, Pandharipande PP, Zorina TD, Haluszczak C, Subbotin VM, Hunter O, Brumfield A, Storkus WJ, Maraskovsky E, Lotze MT: FLT3 ligand induces the generation of functionally active dendritic cells in mice. *Cell Immunol* 1997, 179:174-184.
145. Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E, Maliszewski CR: Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. *Proc Natl Acad Sci U S A* 1999, 96:1036-1041.
146. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC: Flt3 ligand induces tumor regression and antitumor immune responses in vivo. *Nat Med* 1997, 3:625-631.
147. Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR: FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. *Cancer Res* 1998, 58:380-383.
148. Peron JM, Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR: FLT3-ligand administration inhibits liver metastases: role of NK cells. *J Immunol* 1998, 161:6164-6170.
149. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G: Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. *Cancer Res* 2000, 60:3239-3246.
150. Gillessen S, Naumov YN, Nieuwenhuis EE, Exley MA, Lee FS, Mach N, Luster AD, Blumberg RS, Taniguchi M, Balk SP, Strominger JL, Dranoff G, Wilson SB: CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. *Proc Natl Acad Sci U S A* 2003.
151. Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, Damle NK: Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. *J Exp Med* 1992, 176:1595-1604.
152. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA: CTLA-4 can function as a negative regulator of T cell activation. *Immunity* 1994, 1:405-413.
153. Egen JG, Kuhns MS, Allison JP: CTLA-4: new insights into its biological function and use in tumor immunotherapy. *Nat Immunol* 2002, 3:611-618.
154. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW: Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. *Science* 1995, 270:985-988.
155. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. *Immunity* 1995, 3:541-547.

156. Chambers CA, Sullivan TJ, Allison JP: Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. *Immunity* 1997, 7:885-895.
157. Hurwitz AA, Yu TF, Leach DR, Allison JP: CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. *Proc Natl Acad Sci U S A* 1998, 95:10067-10071.
158. van Elsas A, Hurwitz AA, Allison JP: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. *J Exp Med* 1999, 190:355-366.
159. van Elsas A, Suttmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP: Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. *J Exp Med* 2001, 194:481-489.
160. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. *Proc Natl Acad Sci U S A* 2003, 100:4712-4717.
161. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Lieber L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Dranoff G, et al.: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. *Proc Natl Acad Sci U S A* 1998, 95:13141-13146.
162. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Mihm M, Dranoff G: Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. *J Clin Oncol* 2003, 21:3343-3350.

163. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathisen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberger D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. *J Clin Oncol* 2003, 21:624-630.
164. Tsao H, Millman P, Linette GP, Hodi FS, Sober AJ, Goldberg MA, Haluska FG: Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. *Arch Dermatol* 2002, 138:799-802.
165. Zorn E, Hercend T: A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. *Eur J Immunol* 1999, 29:602-607.
166. Ory DS, Neugeboren BA, Mulligan RC: A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. *Proc Natl Acad Sci U S A* 1996, 93:11400-11406.
167. Kozak M: An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. *Nucleic Acids Res* 1987, 15:8125-8148.
168. Basic Local Alignment Search Tool (BLAST); [www.ncbi.nlm.nih.gov/BLAST](http://www.ncbi.nlm.nih.gov/BLAST).
169. Salvesen GS, Duckett CS: IAP proteins: blocking the road to death's door. *Nat Rev Mol Cell Biol* 2002, 3:401-410.
170. Martin SJ: Destabilizing influences in apoptosis: sowing the seeds of IAP destruction. *Cell* 2002, 109:793-796.
171. Silke J, Vaux DL: Two kinds of BIR-containing protein - inhibitors of apoptosis, or required for mitosis. *J Cell Sci* 2001, 114:1821-1827.
172. Liston P, Roy N, Tamai K, Lefebvre C, Baird S, Cherton-Horvat G, Farahani R, McLean M, Ikeda JE, MacKenzie A, Korneluk RG: Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. *Nature* 1996, 379:349-353.
173. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM: ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. *Curr Biol* 2000, 10:1359-1366.
174. Kasof GM, Gomes BC: Livin, a Novel Inhibitor of Apoptosis Protein Family Member. *J Biol Chem* 2001, 276:3238-3246.
175. Itoh M, Kim CH, Palardy G, Oda T, Jiang YJ, Maust D, Yeo SY, Lorick K, Wright GJ, Ariza-McNaughton L, Weissman AM, Lewis J, Chandrasekharappa SC, Chitnis AB: Mind bomb is a ubiquitin ligase that is essential for efficient activation of Notch signaling by Delta. *Dev Cell* 2003, 4:67-82.
176. Grueneberg DA, Pablo L, Hu KQ, August P, Weng Z, Papkoff J: A functional screen in human cells identifies UBF2 as an RNA polymerase II transcription factor that enhances the beta-catenin signaling pathway. *Mol Cell Biol* 2003, 23:3936-3950.

177. Crook NE, Clem RJ, Miller LK: An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. *J Virol* 1993, 67:2168-2174.
178. Birnbaum MJ, Clem RJ, Miller LK: An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. *J Virol* 1994, 68:2521-2528.
179. Clem RJ, Miller LK: Control of programmed cell death by the baculovirus genes p35 and iap. *Mol Cell Biol* 1994, 14:5212-5222.
180. Uren AG, Beilharz T, O'Connell MJ, Bugg SJ, van Driel R, Vaux DL, Lithgow T: Role for yeast inhibitor of apoptosis (IAP)-like proteins in cell division. *Proc Natl Acad Sci U S A* 1999, 96:10170-10175.
181. Fraser AG, James C, Evan GI, Hengartner MO: Caenorhabditis elegans inhibitor of apoptosis protein (IAP) homologue BIR-1 plays a conserved role in cytokinesis. *Curr Biol* 1999, 9:292-301.
182. Roy N, Mahadevan MS, McLean M, Shutler G, Yaraghi Z, Farahani R, Baird S, Besner-Johnston A, Lefebvre C, Kang X, et al.: The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. *Cell* 1995, 80:167-178.
183. Clem RJ, Fechheimer M, Miller LK: Prevention of apoptosis by a baculovirus gene during infection of insect cells. *Science* 1991, 254:1388-1390.
184. Ray CA, Black RA, Kronheim SR, Greenstreet TA, Sleath PR, Salvesen GS, Pickup DJ: Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme. *Cell* 1992, 69:597-604.
185. Takahashi R, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, Salvesen GS, Reed JC: A single BIR domain of XIAP sufficient for inhibiting caspases. *J Biol Chem* 1998, 273:7787-7790.
186. Huang Y, Park YC, Rich RL, Segal D, Myszka DG, Wu H: Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. *Cell* 2001, 104:781-790.
187. Yang Y, Yu X: Regulation of apoptosis: the ubiquitous way. *Faseb J* 2003, 17:790-799.
188. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD: Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. *Science* 2000, 288:874-877.
189. MacFarlane M, Merrison W, Bratton SB, Cohen GM: Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. *J Biol Chem* 2002, 277:36611-36616.
190. Hu S, Yang X: Cellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLO. *J Biol Chem* 2003, 278:10055-10060.
191. Olson MR, Holley CL, Yoo SJ, Huh JR, Hay BA, Kornbluth S: Reaper is regulated by IAP-mediated ubiquitination. *J Biol Chem* 2003, 278:4028-4034.
192. Clustal W; [www.ebi.ac.uk/clustalw/index.html](http://www.ebi.ac.uk/clustalw/index.html).

193. Lin JH, Deng G, Huang Q, Morser J: KIAP, a novel member of the inhibitor of apoptosis protein family. *Biochem Biophys Res Commun* 2000, 279:820-831.
194. Sanna MG, da Silva Correia J, Ducrey O, Lee J, Nomoto K, Schrantz N, Deveraux QL, Ulevitch RJ: IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition. *Mol Cell Biol* 2002, 22:1754-1766.
195. Vucic D, Deshayes K, Ackerly H, Pisabarro MT, Kadkhodayan S, Fairbrother WJ, Dixit VM: SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). *J Biol Chem* 2002, 277:12275-12279.
196. Yang QH, Church-Hajduk R, Ren J, Newton ML, Du C: Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. *Genes Dev* 2003, 17:1487-1496.
197. Wang SL, Hawkins CJ, Yoo SJ, Muller HA, Hay BA: The Drosophila caspase inhibitor DIAP1 is essential for cell survival and is negatively regulated by HID. *Cell* 1999, 98:453-463.
198. Yoo SJ, Huh JR, Muro I, Yu H, Wang L, Wang SL, Feldman RM, Clem RJ, Muller HA, Hay BA: Hid, Rpr and Grim negatively regulate DIAP1 levels through distinct mechanisms. *Nat Cell Biol* 2002, 4:416-424.
199. Ryoo HD, Bergmann A, Gonen H, Ciechanover A, Steller H: Regulation of Drosophila IAP1 degradation and apoptosis by reaper and ubcD1. *Nat Cell Biol* 2002, 4:432-438.
200. Christich A, Kauppila S, Chen P, Sogame N, Ho SI, Abrams JM: The damage-responsive Drosophila gene sickle encodes a novel IAP binding protein similar to but distinct from reaper, grim, and hid. *Curr Biol* 2002, 12:137-140.
201. Tenev T, Zachariou A, Wilson R, Paul A, Meier P: Jafrac2 is an IAP antagonist that promotes cell death by liberating Dronc from DIAP1. *Embo J* 2002, 21:5118-5129.
202. Meier P, Silke J, Leever SJ, Evan GI: The Drosophila caspase DRONC is regulated by DIAP1. *Embo J* 2000, 19:598-611.
203. Muro I, Hay BA, Clem RJ: The Drosophila DIAP1 protein is required to prevent accumulation of a continuously generated, processed form of the apical caspase DRONC. *J Biol Chem* 2002, 277:49644-49650.
204. Ashhab Y, Alian A, Polliack A, Panet A, Ben Yehuda D: Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. *FEBS Lett* 2001, 495:56-60.
205. Parker KC, Bednarek MA, Coligan JE: Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. *J Immunol* 1994, 152:163-175.
206. Harris CP, Lu XY, Narayan G, Singh B, Murty VV, Rao PH: Comprehensive molecular cytogenetic characterization of cervical cancer cell lines. *Genes Chromosomes Cancer* 2003, 36:233-241.

207. Wu CW, Chen GD, Fann CS, Lee AF, Chi CW, Liu JM, Weier U, Chen JY: Clinical implications of chromosomal abnormalities in gastric adenocarcinomas. *Genes Chromosomes Cancer* 2002, 35:219-231.
208. Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A, Isola JJ: Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. *Clin Cancer Res* 2000, 6:1833-1839.
209. Korn WM, Yasutake T, Kuo WL, Warren RS, Collins C, Tomita M, Gray J, Waldman FM: Chromosome arm 20q gains and other genomic alterations in colorectal cancer metastatic to liver, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. *Genes Chromosomes Cancer* 1999, 25:82-90.
210. Barks JH, Thompson FH, Taetle R, Yang JM, Stone JF, Wymer JA, Khavari R, Guan XY, Trent JM, Pinkel D, Nelson MA: Increased chromosome 20 copy number detected by fluorescence in situ hybridization (FISH) in malignant melanoma. *Genes Chromosomes Cancer* 1997, 19:278-285.
211. Tanner MM, Tirkkonen M, Kallioniemi A, Holli K, Collins C, Kowbel D, Gray JW, Kallioniemi OP, Isola J: Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. *Clin Cancer Res* 1995, 1:1455-1461.
212. Celera Discovery System; [myscience.appliedbiosystems.com](http://myscience.appliedbiosystems.com).
213. Kitada S, Pedersen IM, Schimmer AD, Reed JC: Dysregulation of apoptosis genes in hematopoietic malignancies. *Oncogene* 2002, 21:3459-3474.
214. Hersey P, Zhang XD: Overcoming resistance of cancer cells to apoptosis. *J Cell Physiol* 2003, 196:9-18.
215. Newton K, Strasser A: Cell death control in lymphocytes. *Adv Immunol* 2000, 76:179-226.
216. Baliga BC, Kumar S: Role of Bcl-2 family of proteins in malignancy. *Hematol Oncol* 2002, 20:63-74.
217. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. *Nature* 2001, 409:207-211.
218. Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA, Franken KL, Hahne M, Albar JP, Melief CJ, Offringa R: Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. *Proc Natl Acad Sci U S A* 2001, 98:11515-11520.
219. Irmeler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J: Inhibition of death receptor signals by cellular FLIP. *Nature* 1997, 388:190-195.
220. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ: Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. *J Immunol* 1998, 161:2833-2840.

221. Bullani RR, Huard B, Viard-Leveugle I, Byers HR, Irmeler M, Saurat JH, Tschopp J, French LE: Selective expression of FLIP in malignant melanocytic skin lesions. *J Invest Dermatol* 2001, 117:360-364.
222. Peli J, Schroter M, Rudaz C, Hahne M, Meyer C, Reichmann E, Tschopp J: Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. *Embo J* 1999, 18:1824-1831.
223. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. *Nat Med* 1997, 3:917-921.
224. Xing N, Qian J, Bostwick D, Bergstralh E, Young CY: Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. *Prostate* 2001, 48:7-15.
225. Chiodino C, Cesinaro AM, Ottani D, Fantini F, Giannetti A, Trentini GP, Pincelli C: Communication: expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. *J Invest Dermatol* 1999, 113:415-418.
226. Carter BZ, Milella M, Altieri DC, Andreeff M: Cytokine-regulated expression of survivin in myeloid leukemia. *Blood* 2001, 97:2784-2790.
227. Grossman D, McNiff JM, Li F, Altieri DC: Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. *J Invest Dermatol* 1999, 113:1076-1081.
228. Grossman D, McNiff JM, Li F, Altieri DC: Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. *Lab Invest* 1999, 79:1121-1126.
229. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, Cook BP, Dufault MR, Ferguson AT, Gao Y, He TC, Hermeking H, Hiraldo SK, Hwang PM, Lopez MA, Luderer HF, Mathews B, Petroziello JM, Polyak K, Zawel L, Kinzler KW, et al.: Analysis of human transcriptomes. *Nat Genet* 1999, 23:387-388.
230. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J, Fujii Y: Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. *Int J Cancer* 2001, 95:92-95.
231. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC: Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. *N Engl J Med* 1999, 341:452-453.
232. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC: Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. *Lancet* 1998, 351:882-883.
233. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y, Nakagawara A: High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. *Oncogene* 2000, 19:617-623.

234. Islam A, Kageyama H, Hashizume K, Kaneko Y, Nakagawara A: Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin- beta/2B. *Med Pediatr Oncol* 2000, 35:550-553.
235. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, Salles G, Altieri DC, Molina TJ: Prognostic significance of survivin expression in diffuse large B-cell lymphomas. *Blood* 2000, 96:1921-1925.
236. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ: Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. *Gut* 2000, 46:645-650.
237. Sarela AI, Scott N, Ramsdale J, Markham AF, Guillou PJ: Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. *Ann Surg Oncol* 2001, 8:305-310.
238. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. *Cancer Res* 1998, 58:5071-5074.
239. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. *Clin Cancer Res* 2000, 6:127-134.
240. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T, Tanigawa N: Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. *Cancer* 2001, 91:2026-2032.
241. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC: Urine Detection of Survivin and Diagnosis of Bladder Cancer. *Jama* 2001, 285:324-328.
242. Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P: Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. *Cancer Res* 2001, 61:7339-7348.
243. Kashkar H, Haefs C, Shin H, Hamilton-Dutoit SJ, Salvesen GS, Kronke M, Jurgensmeier JM: XIAP-mediated Caspase Inhibition in Hodgkin's Lymphoma-derived B Cells. *J Exp Med* 2003, 198:341-347.
244. Uren GA, O'Rourke K, Aravind L, Pisabarro TM, Seshagiri S, Koonin VE, Dixit MV: Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. *Mol Cell* 2000, 6:961-967.
245. Hong X, Lei L, Glas R: Tumors acquire inhibitor of apoptosis protein (IAP)-mediated apoptosis resistance through altered specificity of cytosolic proteolysis. *J Exp Med* 2003, 197:1731-1743.
246. Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J, Conrad K, Rieber EP: Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. *Cancer Res* 2000, 60:1815-1817.

247. Yagihashi A, Asanuma K, Nakamura M, Araya J, Mano Y, Torigoe T, Kobayashi D, Watanabe N: Detection of anti-survivin antibody in gastrointestinal cancer patients. *Clin Chem* 2001, 47:1729-1731.
248. Yagihashi A, Asanuma K, Tsuji N, Torigoe T, Sato N, Hirata K, Watanabe N: Detection of anti-livin antibody in gastrointestinal cancer patients. *Clin Chem* 2003, 49:1206-1208.
249. Hodi FS, Schmolinger JC, Soiffer RJ, Salgia R, Lynch T, Ritz J, Alyea EP, Yang J, Neuberger D, Mihm M, Dranoff G: ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. *Proc Natl Acad Sci U S A* 2002, 99:6919-6924.
250. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV: Fc receptors are required in passive and active immunity to melanoma. *Proc Natl Acad Sci U S A* 1998, 95:652-656.
251. Curcio C, Di Carlo E, Clynes R, Smyth MJ, Boggio K, Quaglino E, Spadaro M, Colombo MP, Amici A, Lollini PL, Musiani P, Forni G: Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. *J Clin Invest* 2003, 111:1161-1170.
252. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, Saito T, Verbeek S, Bonnerot C, Ricciardi-Castagnoli P, Amigorena S: Fc gamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. *J Exp Med* 1999, 189:371-380.
253. den Haan JM, Bevan MJ: Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. *J Exp Med* 2002, 196:817-827.
254. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV: Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. *J Exp Med* 2002, 195:125-133.
255. Amigorena S: Fc gamma receptors and cross-presentation in dendritic cells. *J Exp Med* 2002, 195:F1-3.
256. Rafiq K, Bergtold A, Clynes R: Immune complex-mediated antigen presentation induces tumor immunity. *J Clin Invest* 2002, 110:71-79.
257. Keene JA, Forman J: Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. *J Exp Med* 1982, 155:768-782.
258. Yu P, Spiotto MT, Lee Y, Schreiber H, Fu YX: Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. *J Exp Med* 2003, 197:985-995.
259. Greenberg PD: Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. *Adv Immunol* 1991, 49:281-355.
260. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H: CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. *Proc Natl Acad Sci U S A* 1999, 96:8633-8638.

261. Qin Z, Blankenstein T: CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. *Immunity* 2000, 12:677-686.
262. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ: Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. *J Exp Med* 1998, 187:693-702.
263. Rubio-Godoy V, Dutoit V, Rimoldi D, Lienard D, Lejeune F, Speiser D, Guillaume P, Cerottini JC, Romero P, Valmori D: Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. *Proc Natl Acad Sci U S A* 2001, 98:10302-10307.
264. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J: Tumor Suppressor NM23-H1 Is a Granzyme A-Activated DNase during CTL-Mediated Apoptosis, and the Nucleosome Assembly Protein SET Is Its Inhibitor. *Cell* 2003, 112:659-672.
265. Fan Z, Beresford PJ, Zhang D, Xu Z, Novina CD, Yoshida A, Pommier Y, Lieberman J: Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A. *Nat Immunol* 2003, 4:145-153.
266. Thomas DA, Du C, Xu M, Wang X, Ley TJ: DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. *Immunity* 2000, 12:621-632.
267. Sharif-Askari E, Alam A, Rheaume E, Beresford PJ, Scotto C, Sharma K, Lee D, DeWolf WE, Nuttall ME, Lieberman J, Sekaly RP: Direct cleavage of the human DNA fragmentation factor-45 by granzyme B induces caspase-activated DNase release and DNA fragmentation. *Embo J* 2001, 20:3101-3113.
268. Jager E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jager D, Oesch F, Knuth A: Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. *Int J Cancer* 1997, 71:142-147.
269. Maeurer MJ, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, Robbins P, Parmiani G, Storkus WJ, Lotze MT: Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. *J Clin Invest* 1996, 98:1633-1641.
270. Kurnick JT, Ramirez-Montagut T, Boyle LA, Andrews DM, Pandolfi F, Durda PJ, Butera D, Dunn IS, Benson EM, Gobin SJ, van den Elsen PJ: A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter. *J Immunol* 2001, 167:1204-1211.

271. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. *Proc Natl Acad Sci U S A* 2002, 99:16168-16173.
272. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. *Immunity* 1999, 10:673-679.
273. Chene P: Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. *Nat Rev Cancer* 2003, 3:102-109.
274. Schreiber H, Wu TH, Nachman J, Kast WM: Immunodominance and tumor escape. *Semin Cancer Biol* 2002, 12:25-31.
275. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL: Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. *Cell* 2000, 102:43-53.
276. Franklin MC, Kadkhodayan S, Ackerly H, Alexandru D, Distefano MD, Elliott LO, Flygare JA, Mausisa G, Okawa DC, Ong D, Vucic D, Deshayes K, Fairbrother WJ: Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). *Biochemistry* 2003, 42:8223-8231.
277. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD: Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. *Cancer Res* 1999, 59:6097-6102.
278. Mahotka C, Krieg T, Krieg A, Wenzel M, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD: Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. *Int J Cancer* 2002, 100:30-36.
279. Harlin H, Reffey SB, Duckett CS, Lindsten T, Thompson CB: Characterization of XIAP-deficient mice. *Mol Cell Biol* 2001, 21:3604-3608.
280. Schmollinger JC, Vonderheide RH, Hoar KM, Maecker B, Schultze JL, Hodi FS, Soiffer RJ, Jung K, Kuroda MJ, Letvin NL, Greenfield EA, Mihm M, Kutok JL, Dranoff G: Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. *Proc Natl Acad Sci U S A* 2003, 100:3398-3403.